Zoledronic Acid to Prevent Bone Loss During Androgen Deprivation Therapy for Prostate Cancer

Phase 2 Completed 60 enrolled Massachusetts General Hospital Dana-Farber Cancer Institute · collab

RandomizedFactorialSingle-blindPrevention

Summary

The primary objective of this study is to determine whether zoledronic acid (Zometa) given once annually increases bone mineral density in men receiving hormone therapy for prostate cancer.

Timeline

Start: 2003-09
Primary completion: 2006-02
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Zoledronic acid	Other / unclassified	—	Intravenous

Zoledronic Acid to Prevent Bone Loss During Androgen Deprivation Therapy for Prostate Cancer

Summary

Timeline

Drugs

Indications